Traders should monitor the progress of the confirmatory Phase III trial for Multikine, as success could validate the earlier positive data and potentially lead to regulatory approval. However, the company's financial instability and history of losses present significant risk. The lack of a minimum offering requirement means the company could receive less capital than needed to complete its trials.
Executive Summary
CEL-SCI Corporation (CVM) is conducting a best-efforts S-1 IPO to raise approximately $13.7 million in net proceeds, primarily to fund the confirmatory Phase III trial of its lead immunotherapy candidate, Multikine, for head and neck cancer. The company presents promising Phase III data showing a 73% 5-year survival rate in a targeted patient population, but faces significant risks including lack of revenue, substantial losses, and uncertainty around regulatory approval.
Key Financial Metrics
Key Facts
- Company is raising $13.7 million via an S-1 IPO to fund development of Multikine, an immunotherapy for head and neck cancer.
- Phase III trial data shows 73% 5-year survival rate in target population vs 45% in control group, with a hazard ratio of 0.35.
- Company reported a net loss of $25.4 million for the year ended September 30, 2025, with no revenue.
- The company has identified substantial doubt about its ability to continue as a going concern.
- Proceeds will be used to fund the confirmatory Phase III trial of Multikine and for general corporate purposes.
Financial Impact
The company estimates $13.7 million in net proceeds from the offering. The company reported a net loss of $25.4 million for the year ended September 30, 2025, with no revenue.
Risk Factors
- The company has substantial doubt about its ability to continue as a going concern.
- The company has no approved products and has never generated revenue.
- Clinical trials are expensive and may not be successful, and regulatory approval is uncertain.
- The company's stock is highly volatile and could be affected by market conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001654954-26-003679 |
| Document: cvm_ex1.htm | 0001654954-26-003679 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 18w ago | 8-K | $1.10 $1.04 | ▲ +5.45% | ▲ +6.23% | $1.59 (−44.55%) |
Jun 15, 2026 19w ago | 424B5 | $1.01 $1.10 | ▼ −8.91% | ▼ −10.16% | $1.59 (−57.43%) |
May 14, 2026 23w ago | 8-K | $1.43 $1.72 | ▲ +20.28% | ▲ +20.34% | $1.59 (+11.19%) |
May 13, 2026 23w ago | 8-K | $1.30 $1.43 | ▼ −10.00% | ▼ −11.23% | $1.59 (−22.31%) |
May 1, 2026 25w ago | S-1/A | $1.69 $1.74 | ▲ +2.96% | ▲ +2.16% | $1.59 (−5.92%) |
Apr 17, 2026 27w ago | S-1 | $3.94 $3.81 | ▼ −3.30% | ▼ −2.65% | $1.59 (−59.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers